Zacks Investment Research on MSN

GSK to boost respiratory & immunology pipeline with $2.2B RAPT buyout

GSK plc GSK announced that it has entered into a definitive agreement to acquire California-based biotech RAPT Therapeutics ...
Morningstar

GSK Sales, Profit Rise on Boost from HIV, Cancer Drugs — Update

GSK posted higher profit as sales for its specialty treatments including HIV, cancer and asthma beat expectations, offsetting lower vaccine sales on weak demand in the U.S. GSK plans to bring five new ...

GSK to buy US biotech behind food allergy drug for $2.2bn

GSK has agreed to acquire Rapt Therapeutics, a US-based biotech whose leading drug combats food allergies, in a deal that ...

GSK to buy RAPT Therapeutics in $2.2 billion deal for promising food allergy therapy

By Pushkala Aripaka Jan 20 (Reuters) - Britain's GSK will buy RAPT Therapeutics for $2.2 billion, adding global rights to the U.S. firm's experimental food allergy drug ozureprubart to its respiratory ...
Wall Street Journal

GSK Lifts Guidance After Specialty Medicines Boost Sales

GSK GSK-1.70%decrease; red down pointing triangle raised its sales and earnings forecasts for the year after its specialty medicines business helped lift sales in the third quarter, the last reporting ...
Wall Street Journal

GSK Sales, Profit Rise on Boost from HIV, Cancer Drugs

GSK’s profit rose on better-than-expected performance of HIV, cancer and asthma treatments, offsetting lower vaccine demand in the U.S. GSK plans to bring five new specialty medicines to market this ...